Epigenetically silenced PTPRO functions as a prognostic marker and tumor suppressor in human lung squamous cell carcinoma

Ming,Fei; Sun,Qianqiang

doi:10.3892/mmr.2017.6665

Epigenetically silenced PTPRO functions as a prognostic marker and tumor suppressor in human lung squamous cell carcinoma

Authors:
- Fei Ming
- Qianqiang Sun
View Affiliations

Affiliations: Department of Thoracic Surgery, Hubei Cancer Hospital, Wuhan, Hubei 430000, P.R. China
Published online on: May 31, 2017 https://doi.org/10.3892/mmr.2017.6665
Pages: 746-754
Copyright: © Ming et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Protein tyrosine phosphatase receptor‑type O (PTPRO), a member of the PTP family, has been frequently reported as potential tumor suppressor in many types of cancer. However, the exact function of PTPRO in lung squamous cell carcinoma (LSCC) remains unclear. Bisulfite sequencing and methylation specific polymerase chain reaction (PCR) were used to identify the methylation status of PTPRO in LSCC cells, and quantitative methylation specific PCR was used to evaluate the methylation levels of PTPRO in LSCC patients. Stably expressing PTPRO vectors were constructed and transfected into H520 and SK‑MES‑1 cells, followed by MTT and colony formation assays, and analysis of tumor weight and volume in in vivo mouse xenograft models. The present study demonstrated that the CpG island of PTPRO exon 1 was obviously hypermethylated in LSCC cells and tissues. The mRNA expression of PTPRO could be restored by treatment with a demethylation agent. Increased methylation and decreased mRNA levels of PTPRO were observed in LSCC samples compared with adjacent healthy tissues, and were associated with poor prognosis of patients. The mRNA expression of PTPRO was negatively correlated with its methylation level in tumors. Functionally, ectopic PTPRO expression in LSCC cells significantly inhibited the proliferation rates, and colony formation, in comparison with control and non‑transfected cells. In vivo assays confirmed the inhibitory effect of PTPRO on LSCC cell growth. In conclusion, these data provided evidence that epigenetic regulation of PTPRO impairs its tumor suppressor role in LSCC, and restoration of PTPRO may be a potential therapeutic strategy.

View Figures

View References

1	Derman BA, Mileham KF, Bonomi PD, Batus M and Fidler MJ: Treatment of advanced squamous cell carcinoma of the lung: A review. Transl Lung Cancer Res. 4:524–532. 2015.PubMed/NCBI
2	Minami H, Isomoto H, Inoue H, Akazawa Y, Yamaguchi N, Ohnita K, Takeshima F, Hayashi T, Nakayama T and Nakao K: Significance of background coloration in endoscopic detection of early esophageal squamous cell carcinoma. Digestion. 89:6–11. 2014. View Article : Google Scholar : PubMed/NCBI
3	Weißenborn C, Ignatov T, Ochel HJ, Costa SD, Zenclussen AC, Ignatova Z and Ignatov A: GPER functions as a tumor suppressor in triple-negative breast cancer cells. J Cancer Res Clin Oncol. 140:713–723. 2014. View Article : Google Scholar : PubMed/NCBI
4	Calì G, Insabato L, Conza D, Bifulco G, Parrillo L, Mirra P, Fiory F, Miele C, Raciti GA, Di Jeso B, et al: GRP78 mediates cell growth and invasiveness in endometrial cancer. J Cell Physiol. 229:1417–1426. 2014. View Article : Google Scholar : PubMed/NCBI
5	Tan B, Anaka M, Deb S, Freyer C, Ebert LM, Chueh AC, Al-Obaidi S, Behren A, Jayachandran A, Cebon J, et al: FOXP3 over-expression inhibits melanoma tumorigenesis via effects on proliferation and apoptosis. Oncotarget. 5:264–276. 2014.PubMed/NCBI
6	Correa TC, Brohem CA, Winnischofer SM, da Silva Cardeal LB, Sasahara RM, Taboga SR, Sogayar MC and Maria-Engler SS: Downregulation of the RECK-tumor and metastasis suppressor gene in glioma invasiveness. J Cell Biochem. 99:156–167. 2006. View Article : Google Scholar : PubMed/NCBI
7	Romagnolo AP, Romagnolo DF and Selmin OI: BRCA1 as target for breast cancer prevention and therapy. Anticancer Agents Med Chem. 15:4–14. 2015. View Article : Google Scholar : PubMed/NCBI
8	Thaler S, Hähnel PS, Schad A, Dammann R and Schuler M: RASSF1A mediates p21Cip1/Waf1-dependent cell cycle arrest and senescence through modulation of the Raf-MEK-ERK pathway and inhibition of Akt. Cancer Res. 69:1748–1757. 2009. View Article : Google Scholar : PubMed/NCBI
9	Wang L, Ge J, Ma T, Zheng Y, Lv S, Li Y and Liu S: Promoter hypermethylation of the cysteine protease RECK may cause metastasis of osteosarcoma. Tumour Biol. 36:9511–9516. 2015. View Article : Google Scholar : PubMed/NCBI
10	Magdinier F, Ribieras S, Lenoir GM, Frappart L and Dante R: Down-regulation of BRCA1 in human sporadic breast cancer; analysis of DNA methylation patterns of the putative promoter region. Oncogene. 17:3169–3176. 1998. View Article : Google Scholar : PubMed/NCBI
11	Dammann R, Schagdarsurengin U, Strunnikova M, Rastetter M, Seidel C, Liu L, Tommasi S and Pfeifer GP: Epigenetic inactivation of the Ras-association domain family 1 (RASSF1A) gene and its function in human carcinogenesis. Histol Histopathol. 18:665–677. 2003.PubMed/NCBI
12	Wiggins RC, Wiggins JE, Goyal M, Wharram BL and Thomas PE: Molecular cloning of cDNAs encoding human GLEPP1, a membrane protein tyrosine phosphatase: Characterization of the GLEPP1 protein distribution in human kidney and assignment of the GLEPP1 gene to human chromosome 12p12-p13. Genomics. 27:174–181. 1995. View Article : Google Scholar : PubMed/NCBI
13	Motiwala T, Ghoshal K, Das A, Majumder S, Weichenhan D, Wu YZ, Holman K, James SJ, Jacob ST and Plass C: Suppression of the protein tyrosine phosphatase receptor type O gene (PTPRO) by methylation in hepatocellular carcinomas. Oncogene. 22:6319–6331. 2003. View Article : Google Scholar : PubMed/NCBI
14	Motiwala T, Kutay H, Ghoshal K, Bai S, Seimiya H, Tsuruo T, Suster S, Morrison C and Jacob ST: Protein tyrosine phosphatase receptor-type O (PTPRO) exhibits characteristics of a candidate tumor suppressor in human lung cancer. Proc Natl Acad Sci USA. 101:13844–13849. 2004. View Article : Google Scholar : PubMed/NCBI
15	Motiwala T, Majumder S, Kutay H, Smith DS, Neuberg DS, Lucas DM, Byrd JC, Grever M and Jacob ST: Methylation and silencing of protein tyrosine phosphatase receptor type O in chronic lymphocytic leukemia. Clin Cancer Res. 13:3174–3181. 2007. View Article : Google Scholar : PubMed/NCBI
16	You YJ, Chen YP, Zheng XX, Meltzer SJ and Zhang H: Aberrant methylation of the PTPRO gene in peripheral blood as a potential biomarker in esophageal squamous cell carcinoma patients. Cancer Lett. 315:138–144. 2012. View Article : Google Scholar : PubMed/NCBI
17	Laczmanska I and Sasiadek MM: Tyrosine phosphatases as a superfamily of tumor suppressors in colorectal cancer. Acta Biochim Pol. 58:467–470. 2011.PubMed/NCBI
18	Hou J, Xu J, Jiang R, Wang Y, Chen C, Deng L, Huang X, Wang X and Sun B: Estrogen-sensitive PTPRO expression represses hepatocellular carcinoma progression by control of STAT3. Hepatology. 57:678–688. 2013. View Article : Google Scholar : PubMed/NCBI
19	Chen L, Juszczynski P, Takeyama K, Aguiar RC and Shipp MA: Protein tyrosine phosphatase receptor-type O truncated (PTPROt) regulates SYK phosphorylation, proximal B-cell-receptor signaling and cellular proliferation. Blood. 108:3428–3433. 2006. View Article : Google Scholar : PubMed/NCBI
20	Liu Z, Hou J, Ren L, He J, Sun B, Sun LZ and Wang S: Protein tyrosine phosphatase receptor type O expression in the tumor niche correlates with reduced tumor growth, angiogenesis, circulating tumor cells and metastasis of breast cancer. Oncol Rep. 33:1908–1914. 2015.PubMed/NCBI
21	Yu M, Lin G, Arshadi N, Kalatskaya I, Xue B, Haider S, Nguyen F, Boutros PC, Elson A, Muthuswamy LB, et al: Expression profiling during mammary epithelial cell three-dimensional morphogenesis identifies PTPRO as a novel regulator of morphogenesis and ErbB2-mediated transformation. Mol Cell Biol. 32:3913–3924. 2012. View Article : Google Scholar : PubMed/NCBI
22	Chien W, Yin D, Gui D, Mori A, Frank JM, Said J, Kusuanco D, Marchevsky A, McKenna R and Koeffler HP: Suppression of cell proliferation and signaling transduction by connective tissue growth factor in non-small cell lung cancer cells. Mol Cancer Res. 4:591–598. 2006. View Article : Google Scholar : PubMed/NCBI
23	Werstuck GH, Lentz SR, Dayal S, Hossain GS, Sood SK, Shi YY, Zhou J, Maeda N, Krisans SK, Malinow MR and Austin RC: Homocysteine-induced endoplasmic reticulum stress causes dysregulation of the cholesterol and triglyceride biosynthetic pathways. J Clin Invest. 107:1263–1273. 2001. View Article : Google Scholar : PubMed/NCBI
24	Jerónimo C, Henrique R, Hoque MO, Ribeiro FR, Oliveira J, Fonseca D, Teixeira MR, Lopes C and Sidransky D: Quantitative RARbeta2 hypermethylation: A promising prostate cancer marker. Clin Cancer Res. 10:4010–4014. 2004. View Article : Google Scholar : PubMed/NCBI
25	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
26	Coutinho-Camillo CM, Lourenço SV, de Araújo Lima L, Kowalski LP and Soares FA: Expression of apoptosis-regulating miRNAs and target mRNAs in oral squamous cell carcinoma. Cancer Genet. 208:382–389. 2015. View Article : Google Scholar : PubMed/NCBI
27	Zhang X, Xu Y, He C, Guo X, Zhang J, He C, Zhang L, Kong M, Chen B and Zhu C: Elevated expression of CCAT2 is associated with poor prognosis in esophageal squamous cell carcinoma. J Surg Oncol. 111:834–839. 2015. View Article : Google Scholar : PubMed/NCBI
28	Jacob ST and Motiwala T: Epigenetic regulation of protein tyrosine phosphatases: Potential molecular targets for cancer therapy. Cancer Gene Ther. 12:665–672. 2005. View Article : Google Scholar : PubMed/NCBI
29	Matozaki T and Kasuga M: Roles of protein-tyrosine phosphatases in growth factor signalling. Cell Signal. 8:13–19. 1996. View Article : Google Scholar : PubMed/NCBI
30	Li SY, Li R, Chen YL, Xiong LK, Wang HL, Rong L and Luo RC: Aberrant PTPRO methylation in tumor tissues as a potential biomarker that predicts clinical outcomes in breast cancer patients. BMC Genet. 15:672014. View Article : Google Scholar : PubMed/NCBI
31	Asbagh LA, Vazquez I, Vecchione L, Budinska E, De Vriendt V, Baietti MF, Steklov M, Jacobs B, Hoe N, Singh S, et al: The tyrosine phosphatase PTPRO sensitizes colon cancer cells to anti-EGFR therapy through activation of SRC-mediated EGFR signaling. Oncotarget. 5:10070–10083. 2014. View Article : Google Scholar : PubMed/NCBI